Glucagonlike Peptide-2 Analogue: A Possible New Approach in the Management of Inflammatory Bowel Disease

TY - JOUR

T1 - Glucagonlike Peptide-2 Analogue

T2 - A Possible New Approach in the Management of Inflammatory Bowel Disease

AU - Arthur, Grier L.

AU - Schwartz, Marshall Z.

AU - Kuenzler, Keith A.

AU - Birbe, Ruth

AU - Neblett, W.

PY - 2004/3

Y1 - 2004/3

N2 - Background/Purpose: Glucagonlike peptide-2α (GLP-2α) has been shown to be a growth factor for the small intestine. This study investigated the benefits of intravenous and intraluminal administration of GLP-2α using a rat model of inflammatory bowel disease (IBD). Methods: Normal Fisher rats and HLA-B27 (IBD) rats were treated for 14 days as follows: Fisher, intravenous saline (n = 6); HLA-B27, intravenous saline (n = 6); HLA-B27, intravenous GLP-2α (50 μg/kg/d; n = 5); Fisher, intraluminal saline (n = 5); HLA-B27, intraluminal saline (n = 5); or intraluminal GLP-2α (50 μg/kg/d; n = 5). Rats were evaluated for frequency of diarrhea, and the bowel was analyzed for gross and microscopic lesions. Statistical evaluations were determined using analysis of variance (ANOVA). A P value of .05 was significant. Results: Intravenous GLP-2α decreased diarrhea and the number of bowel lesions (P < 05). Microscopic inflammation was reduced by 24% but was not statistically significant. Intraluminal GLP-2α decreased the number of small intestine lesions (P < .05) and the microscopic inflammation (P < .05) but did not significantly reduce diarrhea or the overall number of bowel lesions. Conclusions; GLP-2α ameliorates the signs of IBD in HLA-B27 rats. Intravenous GLP-2α reduces diarrhea more effectively than intraluminal administration, and both routes are equally effective in ameliorating inflammation. GLP-2α potentially provides a new modality for the treatment of IBD.

AB - Background/Purpose: Glucagonlike peptide-2α (GLP-2α) has been shown to be a growth factor for the small intestine. This study investigated the benefits of intravenous and intraluminal administration of GLP-2α using a rat model of inflammatory bowel disease (IBD). Methods: Normal Fisher rats and HLA-B27 (IBD) rats were treated for 14 days as follows: Fisher, intravenous saline (n = 6); HLA-B27, intravenous saline (n = 6); HLA-B27, intravenous GLP-2α (50 μg/kg/d; n = 5); Fisher, intraluminal saline (n = 5); HLA-B27, intraluminal saline (n = 5); or intraluminal GLP-2α (50 μg/kg/d; n = 5). Rats were evaluated for frequency of diarrhea, and the bowel was analyzed for gross and microscopic lesions. Statistical evaluations were determined using analysis of variance (ANOVA). A P value of .05 was significant. Results: Intravenous GLP-2α decreased diarrhea and the number of bowel lesions (P < 05). Microscopic inflammation was reduced by 24% but was not statistically significant. Intraluminal GLP-2α decreased the number of small intestine lesions (P < .05) and the microscopic inflammation (P < .05) but did not significantly reduce diarrhea or the overall number of bowel lesions. Conclusions; GLP-2α ameliorates the signs of IBD in HLA-B27 rats. Intravenous GLP-2α reduces diarrhea more effectively than intraluminal administration, and both routes are equally effective in ameliorating inflammation. GLP-2α potentially provides a new modality for the treatment of IBD.

KW - Glucagonlike peptide-2α

KW - HLA-B27 rats

KW - Inflammatory bowel disease

KW - Intestinal inflammation

UR - https://www.scopus.com/pages/publications/1542408629

U2 - 10.1016/j.jpedsurg.2003.11.024

DO - 10.1016/j.jpedsurg.2003.11.024

M3 - Article

C2 - 15017568

SN - 0022-3468

VL - 39

SP - 448

EP - 452

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

IS - 3

ER -